CL2014001155A1 - Metodo para reducir el acido urico en el suero de un sujeto con hiperuricemia, administrando un primer agente reductor de urato y un segundo agente reductor de urato; composicion farmaceutica; kit farmaceutico; uso en el tratamiento de gota aguda, cronica, moderada, refractaria o severa. - Google Patents
Metodo para reducir el acido urico en el suero de un sujeto con hiperuricemia, administrando un primer agente reductor de urato y un segundo agente reductor de urato; composicion farmaceutica; kit farmaceutico; uso en el tratamiento de gota aguda, cronica, moderada, refractaria o severa.Info
- Publication number
- CL2014001155A1 CL2014001155A1 CL2014001155A CL2014001155A CL2014001155A1 CL 2014001155 A1 CL2014001155 A1 CL 2014001155A1 CL 2014001155 A CL2014001155 A CL 2014001155A CL 2014001155 A CL2014001155 A CL 2014001155A CL 2014001155 A1 CL2014001155 A1 CL 2014001155A1
- Authority
- CL
- Chile
- Prior art keywords
- reducing agent
- urate
- hyperuricemia
- refractory
- moderate
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title 3
- 239000003638 chemical reducing agent Substances 0.000 title 2
- 201000005569 Gout Diseases 0.000 title 1
- 201000001431 Hyperuricemia Diseases 0.000 title 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000002966 serum Anatomy 0.000 title 1
- 229940116269 uric acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059394 WO2013066349A1 (fr) | 2011-11-04 | 2011-11-04 | Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001155A1 true CL2014001155A1 (es) | 2015-01-16 |
Family
ID=48192533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001155A CL2014001155A1 (es) | 2011-11-04 | 2014-05-02 | Metodo para reducir el acido urico en el suero de un sujeto con hiperuricemia, administrando un primer agente reductor de urato y un segundo agente reductor de urato; composicion farmaceutica; kit farmaceutico; uso en el tratamiento de gota aguda, cronica, moderada, refractaria o severa. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2773336A4 (fr) |
| JP (1) | JP6202633B2 (fr) |
| KR (1) | KR20140121383A (fr) |
| CN (2) | CN109908124A (fr) |
| AU (1) | AU2011380507B2 (fr) |
| CA (1) | CA2859686C (fr) |
| CL (1) | CL2014001155A1 (fr) |
| IL (1) | IL232386A0 (fr) |
| MX (1) | MX357507B (fr) |
| NZ (1) | NZ624708A (fr) |
| SG (1) | SG11201402032RA (fr) |
| WO (1) | WO2013066349A1 (fr) |
| ZA (1) | ZA201403575B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836209A4 (fr) * | 2012-04-13 | 2015-11-25 | Cymabay Therapeutics Inc | Méthode de traitement de l'hyperuricémie, faisant appel à l'halofénate ou à l'acide halofénique et à un agent anti-inflammatoire, chez les patients souffrant de goutte |
| JP6368756B2 (ja) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
| CN108014108A (zh) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用 |
| US11446317B2 (en) | 2017-10-26 | 2022-09-20 | Otsuka Pharmaceutical Co., Ltd. | Inositol phosphate-containing composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| WO2011032175A1 (fr) * | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Formulations combinées de tranilast et d'allopurinol et procédés associées à celles-ci |
-
2011
- 2011-11-04 EP EP11875114.8A patent/EP2773336A4/fr not_active Withdrawn
- 2011-11-04 KR KR1020147015169A patent/KR20140121383A/ko active IP Right Grant
- 2011-11-04 MX MX2014005400A patent/MX357507B/es active IP Right Grant
- 2011-11-04 AU AU2011380507A patent/AU2011380507B2/en not_active Ceased
- 2011-11-04 CN CN201910004813.0A patent/CN109908124A/zh active Pending
- 2011-11-04 SG SG11201402032RA patent/SG11201402032RA/en unknown
- 2011-11-04 CA CA2859686A patent/CA2859686C/fr not_active Expired - Fee Related
- 2011-11-04 WO PCT/US2011/059394 patent/WO2013066349A1/fr active Application Filing
- 2011-11-04 JP JP2014541011A patent/JP6202633B2/ja not_active Expired - Fee Related
- 2011-11-04 NZ NZ624708A patent/NZ624708A/en not_active IP Right Cessation
- 2011-11-04 CN CN201180076191.4A patent/CN104066427A/zh active Pending
-
2014
- 2014-04-30 IL IL232386A patent/IL232386A0/en unknown
- 2014-05-02 CL CL2014001155A patent/CL2014001155A1/es unknown
- 2014-05-16 ZA ZA2014/03575A patent/ZA201403575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201403575B (en) | 2015-11-25 |
| EP2773336A4 (fr) | 2015-06-03 |
| CN104066427A (zh) | 2014-09-24 |
| EP2773336A1 (fr) | 2014-09-10 |
| MX2014005400A (es) | 2015-02-12 |
| CA2859686C (fr) | 2018-09-11 |
| JP6202633B2 (ja) | 2017-09-27 |
| JP2014532758A (ja) | 2014-12-08 |
| MX357507B (es) | 2018-07-12 |
| NZ624708A (en) | 2015-11-27 |
| KR20140121383A (ko) | 2014-10-15 |
| AU2011380507B2 (en) | 2017-06-15 |
| CA2859686A1 (fr) | 2013-05-10 |
| IL232386A0 (en) | 2014-06-30 |
| SG11201402032RA (en) | 2014-09-26 |
| CN109908124A (zh) | 2019-06-21 |
| WO2013066349A1 (fr) | 2013-05-10 |
| AU2011380507A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003548A1 (es) | Composicion farmaceutica de liberacion modificada que comprende esferas de liberacion inmediata y esferas de liberacion demorada de acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico (febuxostat), inhibidor selectivo de xantina oxidorreductasa; forma de dosificacion; y metodo de tratamiento para gota, entre otros. | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| BR112013022332A2 (pt) | métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| WO2009109927A3 (fr) | Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| WO2012129084A3 (fr) | Inhibiteurs de la glucosylcéramide synthase | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
| CL2014001155A1 (es) | Metodo para reducir el acido urico en el suero de un sujeto con hiperuricemia, administrando un primer agente reductor de urato y un segundo agente reductor de urato; composicion farmaceutica; kit farmaceutico; uso en el tratamiento de gota aguda, cronica, moderada, refractaria o severa. | |
| CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
| CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
| CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
| CL2013001564A1 (es) | Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica. | |
| CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
| CL2015000857A1 (es) | Una composicion farmaceutica que consiste en una primera capa que comprende metformina y una segunda capa que comprende gemigliptina; su metodo de preparacion, util para la prevencion y el tratamiento de la diabetes. | |
| CL2014001157A1 (es) | Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato. | |
| GB201014391D0 (en) | Drug composition and its use in therapy | |
| CL2013002006A1 (es) | Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. |